Prelude Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PRLD and other ETFs, options, and stocks.About PRLD
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines.
CEOKrishna Vaddi
CEOKrishna Vaddi
Employees131
Employees131
HeadquartersWilmington, Delaware
HeadquartersWilmington, Delaware
Founded2016
Founded2016
Employees131
Employees131
PRLD Key Statistics
Market cap129.70M
Market cap129.70M
Price-Earnings ratio-1.39
Price-Earnings ratio-1.39
Dividend yield—
Dividend yield—
Average volume555.90K
Average volume555.90K
High today$2.30
High today$2.30
Low today$2.13
Low today$2.13
Open price$2.18
Open price$2.18
Volume318.18K
Volume318.18K
52 Week high$4.22
52 Week high$4.22
52 Week low$0.6101
52 Week low$0.6101
Stock Snapshot
With a market cap of 129.7M, Prelude Therapeutics(PRLD) trades at $2.26. The stock has a price-to-earnings ratio of -1.39.
On 2026-01-14, Prelude Therapeutics(PRLD) stock traded between a low of $2.13 and a high of $2.30. Shares are currently priced at $2.26, which is +6.2% above the low and -1.9% below the high.
Prelude Therapeutics(PRLD) shares are trading with a volume of 318.18K, against a daily average of 555.9K.
In the last year, Prelude Therapeutics(PRLD) shares hit a 52-week high of $4.22 and a 52-week low of $0.61.
In the last year, Prelude Therapeutics(PRLD) shares hit a 52-week high of $4.22 and a 52-week low of $0.61.
People also own
Based on the portfolios of people who own PRLD. This list is generated using Robinhood data, and it’s not a recommendation.